X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2251) 2251
Magazine Article (6) 6
Book Chapter (5) 5
Government Document (3) 3
Newsletter (3) 3
Conference Proceeding (2) 2
Publication (2) 2
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1507) 1507
animals (878) 878
aniline compounds - therapeutic use (859) 859
male (826) 826
female (700) 700
aniline compounds - pharmacology (581) 581
mice (400) 400
middle aged (383) 383
aged (355) 355
oncology (315) 315
adult (314) 314
pharmacology & pharmacy (305) 305
rats (300) 300
aniline compounds (266) 266
aniline compounds - chemistry (246) 246
antineoplastic agents - therapeutic use (228) 228
aniline (227) 227
cell line, tumor (222) 222
cancer (205) 205
aniline compounds - administration & dosage (191) 191
apoptosis (182) 182
analysis (160) 160
protein kinase inhibitors - therapeutic use (160) 160
antineoplastic agents - pharmacology (159) 159
proteins (155) 155
aniline compounds - adverse effects (154) 154
aged, 80 and over (152) 152
mutation (146) 146
lung neoplasms - drug therapy (143) 143
dose-response relationship, drug (142) 142
aniline compounds - metabolism (141) 141
alzheimer's disease (139) 139
biochemistry & molecular biology (137) 137
neurosciences (137) 137
chemistry, medicinal (131) 131
research (129) 129
expression (128) 128
cell biology (126) 126
apoptosis - drug effects (119) 119
positron-emission tomography (119) 119
carcinoma, non-small-cell lung - drug therapy (117) 117
aniline compounds - pharmacokinetics (115) 115
chemistry, multidisciplinary (113) 113
alzheimer disease - diagnostic imaging (111) 111
activation (109) 109
toxicology (109) 109
clinical trials as topic (108) 108
time factors (107) 107
research article (106) 106
sulfonamides - pharmacology (104) 104
treatment outcome (104) 104
disease models, animal (100) 100
in-vitro (100) 100
protein kinase inhibitors - pharmacology (100) 100
quinolines - therapeutic use (99) 99
care and treatment (98) 98
erbb receptors - genetics (97) 97
kinases (95) 95
multidisciplinary sciences (95) 95
nitriles - therapeutic use (95) 95
chemotherapy (94) 94
inhibitors (94) 94
structure-activity relationship (94) 94
calcium - metabolism (93) 93
acrylamides - therapeutic use (91) 91
medicine (90) 90
brain (89) 89
cells, cultured (88) 88
rats, sprague-dawley (86) 86
amyloid beta-peptides - metabolism (85) 85
lung neoplasms - genetics (85) 85
brain - diagnostic imaging (84) 84
drug synergism (84) 84
cell proliferation - drug effects (83) 83
cells (83) 83
hematology (83) 83
toxicity (83) 83
inhibition (82) 82
resistance (82) 82
tumors (82) 82
aniline compounds - chemical synthesis (81) 81
science (81) 81
tyrosine (81) 81
medicine & public health (80) 80
sulfonamides - therapeutic use (79) 79
brain - metabolism (78) 78
carcinoma, non-small-cell lung - genetics (77) 77
chemistry (77) 77
phosphorylation (77) 77
cell survival - drug effects (76) 76
derivatives (76) 76
lung cancer (76) 76
pet (76) 76
therapy (76) 76
adolescent (75) 75
signal transduction (75) 75
health aspects (74) 74
neoplasms - drug therapy (74) 74
clinical neurology (72) 72
pyrimidines - therapeutic use (72) 72
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2044) 2044
German (92) 92
Italian (40) 40
French (35) 35
Japanese (34) 34
Russian (18) 18
Spanish (11) 11
Chinese (10) 10
Polish (7) 7
Bulgarian (1) 1
Croatian (1) 1
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British journal of haematology, ISSN 0007-1048, 2015, Volume 168, Issue 1, pp. 69 - 81
Summary Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and... 
BCR‐ABL1 | CML | tyrosine kinase inhibitor | bosutinib | chronic myeloid leukaemia | Chronic myeloid leukaemia | Tyrosine kinase inhibitor | Bosutinib | BCR-ABL1 | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | MOLECULAR RESPONSES | DASATINIB | NILOTINIB | RESISTANT | INTERFERON-ALPHA | IN-VITRO | PATIENTS RECEIVING IMATINIB | INHIBITOR | HEMATOLOGY | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Odds Ratio | Benzamides - adverse effects | Aniline Compounds - administration & dosage | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Haematological Malignancy
Journal Article
Journal of the American Society of Nephrology, ISSN 1533-3450, 2017, Volume 28, Issue 9, pp. 2756 - 2767
Journal Article
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2015, Volume 15, Issue 6, pp. 314 - 322
Journal Article
The oncologist (Dayton, Ohio), ISSN 1549-490X, 2011, Volume 16, Issue 5, pp. 566 - 578
Src is believed to play an important role in cancer, and several agents targeting Src are in clinical development. Design. We reviewed Src structure and... 
Dasatinib | Solid tumor | Biologic | Bosutinib | Src inhibitors | Saracatinib | SARACATINIB AZD0530 | ACTIVATION | PROTEIN-TYROSINE KINASES | PHASE-II | CELL-CYCLE ARREST | DASATINIB BMS-354825 | GROWTH-FACTOR RECEPTOR | COLON-CANCER CELLS | ONCOLOGY | PROSTATE-CANCER | C-SRC | Humans | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Pyrimidines - chemistry | Thiazoles - adverse effects | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Benzodioxoles - adverse effects | Benzodioxoles - chemistry | Benzodioxoles - therapeutic use | Quinazolines - chemistry | Quinolines - chemistry | src-Family Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols | Clinical Trials as Topic | Antineoplastic Agents - chemistry | Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Nitriles - chemistry | Pyrimidines - adverse effects | Quinazolines - adverse effects | Thiazoles - chemistry | Quinolines - therapeutic use | Aniline Compounds - chemistry | Aniline Compounds - therapeutic use | Aniline Compounds - adverse effects | Nitriles - adverse effects | src-Family Kinases - chemistry | src-Family Kinases - genetics | Quinolines - adverse effects | Nitriles - therapeutic use | Cancer Biology
Journal Article
Oncogene, ISSN 1476-5594, 2009, Volume 27, Issue S1, pp. S149 - S157
Cancer cells show deviant behavior that induces apoptotic signaling. To survive, cancer cells typically acquire changes enabling evasion of death signals. One... 
Bcl-2 | Drug resistance and ABT-737 | BH3 mimetic | Apoptosis | Cancer | PROAPOPTOTIC ACTIVITY | BIOCHEMISTRY & MOLECULAR BIOLOGY | MIMETIC ABT-737 | BCL-2 FAMILY PROTEINS | apoptosis | OUTER MITOCHONDRIAL-MEMBRANE | ANTIAPOPTOTIC BCL-2 | SMALL-MOLECULE INHIBITOR | CELL BIOLOGY | CYTOCHROME-C | SURVIVAL-PROMOTING PROTEINS | ONCOLOGY | X-L | GENETICS & HEREDITY | CHRONIC LYMPHOCYTIC-LEUKEMIA | cancer | drug resistance and ABT-737 | Neoplasms - metabolism | Sulfones - therapeutic use | Multigene Family | Proto-Oncogene Proteins c-bcl-2 - physiology | Apoptosis - drug effects | Humans | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Piperazines - chemistry | Structure-Activity Relationship | Nitrophenols - chemistry | Drug Delivery Systems | Benzamides - therapeutic use | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Thionucleotides - chemistry | Sulfones - chemistry | Drug Design | Proto-Oncogene Proteins c-bcl-2 - chemistry | Antineoplastic Agents - pharmacology | Biphenyl Compounds - chemistry | Antineoplastic Agents - classification | Pyrroles - therapeutic use | Dimerization | Benzamides - chemistry | Binding, Competitive | Protein Structure, Tertiary | Sulfonamides - chemistry | Thionucleotides - therapeutic use | Clinical Trials as Topic | Mitochondria - drug effects | Antineoplastic Agents - chemistry | Sulfonamides - pharmacology | Piperazines - pharmacology | Neoplasms - drug therapy | Animals | Sulfonamides - therapeutic use | Pyrroles - chemistry | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Mice | Aniline Compounds - chemistry | Aniline Compounds - therapeutic use | Mitochondria - physiology | Drug Screening Assays, Antitumor | Proteins | Signal transduction | Oncology | Molecular biology
Journal Article
Cancer discovery, ISSN 2159-8290, 2014, Volume 4, Issue 9, pp. 1046 - 1061
Journal Article
Cancer Research, ISSN 0008-5472, 09/2006, Volume 66, Issue 17, pp. 8731 - 8739
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 3, pp. 231 - 237
Journal Article